Astellas Pharma Inc. has been involved in substantial corporate activities recently, resulting in a series of notable developments. The firm has announced an
Equity Buyback of 30,000,000 shares for a whopping ¥50,000 million. Additionally, it has entered into significant collaborations with multiple firms, including one with AviadoBio over the gene therapy
AVB-101, set to target Frontotemporal Dementia and other indications. Astellas has also faced some concerns, with an employee being indicted by China's prosecutors. In research and innovative efforts, Astellas has launched the new
Life Sciences Center in Cambridge, Massachusetts, aiming to accelerate breakthrough therapy's discovery. They've also broken ground on a €330 million state-of-the-art
facility in Tralee, Ireland. In product development, the firm has unveiled
DIGITIVA™, their novel heart failure management system, and received FDA approval for gastric cancer therapy. Moreover, the firm obtained approval for
VYLOY™ as a treatment for Advanced Gastric and GEJ Cancer from the U.S FDA. Even with the purchase of new innovation centers, a significant layoff was reported. The firm cut staff at Bavarian, BenevolentAI, Chroma Medicine, and Nvelop Therapeutics. Also, Astellas Gene Therapies plans to close its Biomanufacturing Facility, affecting about 100 Employees.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Sat, 14 Dec 2024 10:46:32 GMT -
Rating 4
- Innovation 7
- Information 7
- Rumor -6
